| The chromatin accessibility landscape of primary human cancers MR Corces, JM Granja, S Shams, BH Louie, JA Seoane, W Zhou, ... Science 362 (6413), eaav1898, 2018 | 935 | 2018 |
| A comprehensive pan-cancer molecular study of gynecologic and breast cancers AC Berger, A Korkut, RS Kanchi, AM Hegde, W Lenoir, W Liu, Y Liu, ... Cancer cell 33 (4), 690-705. e9, 2018 | 548 | 2018 |
| Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas LA Donehower, T Soussi, A Korkut, Y Liu, A Schultz, M Cardenas, X Li, ... Cell reports 28 (5), 1370-1384. e5, 2019 | 513 | 2019 |
| Genomic, pathway network, and immunologic features distinguishing squamous carcinomas JD Campbell, C Yau, R Bowlby, Y Liu, K Brennan, H Fan, AM Taylor, ... Cell reports 23 (1), 194-212. e6, 2018 | 290 | 2018 |
| Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA DM Kurtz, J Soo, L Co Ting Keh, S Alig, JJ Chabon, BJ Sworder, A Schultz, ... Nature biotechnology 39 (12), 1537-1547, 2021 | 177 | 2021 |
| A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-β superfamily A Korkut, S Zaidi, RS Kanchi, S Rao, NR Gough, A Schultz, X Li, ... Cell systems 7 (4), 422-437. e7, 2018 | 143 | 2018 |
| Reconstruction of tissue-specific metabolic networks using CORDA A Schultz, AA Qutub PLoS computational biology 12 (3), e1004808, 2016 | 126 | 2016 |
| Inferring gene expression from cell-free DNA fragmentation profiles MS Esfahani, EG Hamilton, M Mehrmohamadi, BY Nabet, SK Alig, ... Nature biotechnology 40 (4), 585-597, 2022 | 76 | 2022 |
| Large-scale characterization of drug responses of clinically relevant proteins in cancer cell lines W Zhao, J Li, MJM Chen, Y Luo, Z Ju, NK Nesser, K Johnson-Camacho, ... Cancer cell 38 (6), 829-843. e4, 2020 | 49 | 2020 |
| A crowdsourcing approach to developing and assessing prediction algorithms for AML prognosis DP Noren, BL Long, R Norel, K Rrhissorrakrai, K Hess, CW Hu, ... PLoS computational biology 12 (6), e1004890, 2016 | 35 | 2016 |
| Testing frameworks for personalizing bipolar disorder AL Cochran, A Schultz, MG McInnis, DB Forger Translational psychiatry 8 (1), 36, 2018 | 19 | 2018 |
| Predicting internal cell fluxes at sub-optimal growth A Schultz, AA Qutub BMC systems biology 9, 1-12, 2015 | 17 | 2015 |
| A comparison of mathematical models of mood in bipolar disorder AL Cochran, A Schultz, MG McInnis, DB Forger Computational neurology and psychiatry, 315-341, 2017 | 15 | 2017 |
| Identifying cancer specific metabolic signatures using constraint-based models A Schultz, S Mehta, CW Hu, FW Hoff, TM Horton, SM Kornblau, AA Qutub PACIFIC SYMPOSIUM ON BIOCOMPUTING 2017, 485-496, 2017 | 7 | 2017 |
| Distinct molecular subtypes of classic Hodgkin lymphoma identified by comprehensive noninvasive profiling SK Alig, M Shahrokh Esfahani, MY Li, RM Adams, A Garofalo, MC Jin, ... Blood 140 (Supplement 1), 1295-1296, 2022 | 6 | 2022 |
| MRD-negativity as a potential surrogate endpoint after frontline DLBCL therapy: pooled analysis of trials & implications for clinical trial design M Roschewski, DM Kurtz, J Westin, RC Lynch, C Macaulay, C Kuffer, ... Blood 140 (Supplement 1), 785-786, 2022 | 5 | 2022 |
| Ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq JM Isbell, BT Li, P Razavi, J Reis-Filo, SY Liu, P Selenica, P Adusumilli, ... Cancer Research 83 (7_Supplement), 3375-3375, 2023 | 3 | 2023 |
| SAMMI: a semi-automated tool for the visualization of metabolic networks A Schultz, R Akbani Bioinformatics 36 (8), 2616-2617, 2020 | 3 | 2020 |
| Viral cfDNA profiling reveals distinct EBV subtypes and stratifies risk in Hodgkin lymphomas A Garofalo, SK Alig, J Schroers-Martin, RM Shyam, M Olsen, DM Kurtz, ... Blood 140 (Supplement 1), 1318-1319, 2022 | 2 | 2022 |
| Ultrasensitive MRD profiling predicts outcomes in DLBCL after frontline therapy with tafasitamab in combination with lenalidomide and R-CHOP DM Kurtz, GJ Hogan, A Schultz, K Kopeckova, C Kuffer, D Blair, S Wagner, ... Blood 140 (Supplement 1), 3498-3499, 2022 | 2 | 2022 |
Amina Ann QutubAssociate Professor, Biomedical Engineering, University of Texas, San AntonioVerified email at utsa.edu
